C12N 2710/16511
Roseolovirus
Official title: Roseolovirus, e.g. human herpesvirus 6, 7
C12N2710/16511 (Roseolovirus) appears on 36 US grants and 51 published applications in this corpus.
Search patents in C12N- Granted patents
- 36
- Published applications
- 51
- Assignees
- 28
- Inventors
- 74
- Latest grant
- 13 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 2 | 0 |
| 2001 | 1 | 1 |
| 2002 | 0 | 1 |
| 2003 | 1 | 0 |
| 2004 | 0 | 1 |
| 2005 | 1 | 2 |
| 2006 | 0 | 2 |
| 2007 | 0 | 2 |
| 2008 | 1 | 1 |
| 2009 | 0 | 4 |
| 2010 | 1 | 3 |
| 2011 | 4 | 2 |
| 2012 | 1 | 4 |
| 2013 | 1 | 4 |
| 2014 | 1 | 3 |
| 2015 | 3 | 1 |
| 2016 | 1 | 2 |
| 2017 | 0 | 2 |
| 2018 | 1 | 0 |
| 2019 | 2 | 3 |
| 2020 | 5 | 4 |
| 2021 | 0 | 4 |
| 2022 | 1 | 1 |
| 2023 | 0 | 0 |
| 2024 | 0 | 3 |
| 2025 | 0 | 0 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/16522New viral proteins or individual genes, new structural or functional aspects ofIndexing code27
- C12N 2710/16541Use of virus, viral particle or viral elements as a vectorIndexing code4
- C12N 2710/16521Viruses as suchIndexing code3
- C12N 2710/16532Use of virus as therapeutic agent, other than vaccineIndexing code3
- C12N 2710/16551Methods of production or purification of viral materialIndexing code3
- C12N 2710/16571Demonstrated in vivo effectIndexing code3
- C12N 2710/16523Virus like particles [vlp]Indexing code0
- C12N 2710/16531Uses of virus other than therapeutic or vaccineIndexing code0
All 12 subgroupsShow fewer
Recent patents
- Compositions and methods for delivering CFTR polypeptides13 Jan 2026US 12,522,636 B2Krystal Biotech, Inc.
- Mesothelin vaccines and model systems29 Mar 2022US 11,285,197 B2The Johns Hopkins University
- Vaccine against beta-herpesvirus infection and use thereof24 Nov 2020US 10,842,863 B2
- Compositions and methods for delivering CFTR polypeptides10 Nov 2020US 10,829,529 B2Krystal Biotech, Inc.
- Inhibition of TCR signaling with peptide variants21 Jan 2020US 10,538,558 B2Signablok, Inc.
- Compositions and Methods for Delivering CFTR Polypeptides30 Apr 2026US 2026/0116934 A1Krystal Biotech, Inc.
- Peptides with anti-angiogenic activity21 Nov 2024US 2024/0382555 A1CHEIRONTECH S.r.l.
- Polypeptide11 Apr 2024US 2024/0117048 A1UCL Business PLC
- Method for inhibiting adventitious viral infection14 Mar 2024US 2024/0085403 A1
- Inhibition Of TCR Signaling With Peptide Variants18 Aug 2022US 2022/0259267 A9Signablok, Inc.
Most cited
By later US patents
- Screening method for chronic immune dysfunction syndrome35US 5,426,028 ARush-Presbyterian-St. Luke's Medical Center · 1995
- Screening kit and method for diagnosing chronic immune dysfunction syndrome34US 5,538,856 AThe Regents of the University of California · 1996
- Methods of detecting the presence of human herpesvirus-7 infection26US 5,230,997 AThe United States of America as represented by the Department of Health and Human Services · 1993
- Mesothelin vaccines and model systems6US 9,296,784 B2The Johns Hopkins University · 2016
- Compositions and methods for delivering CFTR polypeptides4US 10,829,529 B2Krystal Biotech, Inc. · 2020